MOLNOVA
HIT YOUR RESEARCH TO LEAD

Datasheet (Version 1.0)

Product Name	:	Ningetinib
Synonyms	:	CT-053,CT053PTSA
Cat No.	:	M22115
CAS Number	:	1394820-69-9
Molecular Formula	:	C31H29FN4O5
Formula Weight	:	556.58
Chemical Name	:	——
Description	:	Ningetinib (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.In cell-based functional assays, Ningetinib inhibits VEGF and HGF-stimulated HUVEC proliferation and microvascular angiogenesis in rat aortic rings with IC50 values of 6.3 and 8.6 nM, respectively.In the orthotopic U87MG human glioblastoma xenograft model, Ningetinib prolongs the median survival time and yields a significant increase in life-span value (ILS=32%) at an oral dose of 20 mg/kg/day (dosed 21 days) versus the vehicle-treated group. When single dosed orally (3 mg/kg) to U87MG tumor-bearing nude mice, Ningetinib potently inhibits the phosphorylation of c-Met and its downstream signaling kinases AKT and ERK1/2 for up to 6 hours in tumor tissues.
Pathway	:	Angiogenesis
Target	:	c-Met/HGFR
Receptor	:	c-Met; VEGFR2; AXL
Solubility	:	DMSO:15 mg/mL (26.95 mM; Need ultrasonic)
SMILES	:	Cc1c(C(=O)Nc2ccc(Oc3ccnc4cc(OCC(C)(C)O)ccc34)c(F)c2)c(=O)n(-c2ccccc2)n1C
Storage	:	(-20℃)
Stability	:	≥ 2 years
Reference	:	



1.Ning Xi, et al. Abstract 1755: CT053PTSA, a novel c-MET and VEGFR2 inhibitor, potently suppresses angiogenesis and tumor growth. Cancer Res 2014;74(19 Suppl):Abstract nr 1755.